Summary: Magnetic resonance imaging (MRI) has played a central role in the diagnosis and management of multiple sclerosis (MS). In addition, MRI metrics have become key supportive outcome measures to explore drug efficacy in clinical trials. Conventional MRI measures have contributed to the understanding of MS pathophysiology at the macroscopic level yet have failed to provide a complete picture of underlying MS pathology. They also show relatively weak relationships to clinical status such as predictive strength for clinical progression. Advanced quantitative MRI measures such as magnetization transfer, spectroscopy, diffusion imaging, and relaxometry techniques are somewhat more specific and sensitive for underlying pathology. These measures are particularly useful in revealing diffuse damage in cerebral white and gray matter and therefore may help resolve the dissociation between clinical and conventional MRI findings. In this article, we provide an overview of the array of tools available with brain and spinal cord MRI technology as it is applied to MS. We review the most recent data regarding the role of conventional and advanced MRI techniques in the assessment of MS. We focus on the most relevant pathologic and clinical correlation studies relevant to these measures.
INTRODUCTION
MRI has emerged as a powerful noninvasive tool to assist in the diagnosis and monitoring of multiple sclerosis (MS) . In addition, MRI has emerged as a key supportive therapeutic outcome measure in MS-related clinical trials. 1 It has also aided in the understanding of the pathophysiology of the disease.
The study of MRI in MS has been flourishing in the field of research in recent years. Studies examining the conventional MRI-based measures, including CNS atrophy and lesions (T2 hyperintense, T1 hypointense, and gadolinium [Gd] enhancing) have uncovered remarkable information in the last two decades.
1,2 These measures have not only provided the basic framework for the clinical diagnosis and management of MS, but they have also shed light on the underlying mechanisms of MS disease processes and provided surrogate outcome measures for clinical trials. 1 However, mounting evidence suggests that these measures lack the specificity required for analyzing the underlying pathology and fail to capture clinically-relevant diffuse occult disease affecting the cerebral white matter (WM) and gray matter (GM). Conventional lesion measures show generally weak correlations with clinical status as measured by the Expanded Disability Status Scale and are unreliable for predicting clinical progression. [1] [2] [3] These shortcomings contribute to the clinical MRI paradox seen in research and clinical settings.
The limitations of conventional MRI surrogates have driven investigators to develop better measures, including those that capture diffuse destructive aspects of the disease occurring throughout the CNS. Years of research have yielded technological advances leading to the development of advanced MRI measures, such as magnetization transfer (MT), magnetic resonance spectroscopy (MRS), diffusion imaging, and relaxometric techniques that are relatively more specific and sensitive for underlying pathology. 1 These encouraging techniques hold promise in the field of MS MRI research, but their relevance to clinical and investigational settings remains unproven.
In this article, we will provide an overview of the array of tools available with MRI technology as it is applied to brain and spinal cord imaging in patients with MS. We will focus on the recent developments that have unfolded in the field of conventional and advanced MRI. Due to space limitations, we shall not include a review of optic nerve or functional brain imaging in patients with MS, which have been recently reviewed in this journal and elsewhere. 4 -6 
T2-hyperintense lesions
MS plaques on conventional proton-density and T2-weighted brain images appear as bright areas and are often referred to as T2-hyperintense lesions (FIG. 1) . Such lesions are typically oval to ovoid in shape and 5 mm or greater in diameter (FIG. 1) . Hyperintensities in the brain are more common in the WM than GM on these conventional sequences. Lesions commonly affect the periventricular WM regions, the inner surface of the corpus callosum, the juxtacortical gray-white junction, the infratentorial brain regions, and the spinal cord (FIG.  1) . In many patients, finger-like hyperintensities perpendicular to the lateral ventricles can be appreciated. These so-called "Dawson's fingers" are believed to reflect perivenular inflammation seen histologically in MS (FIG. 1) . Some of the T2-hyperintense lesions may resolve and wane over time, as reviewed recently in this journal. 7 However, most newly formed T2 lesions chronically persist as "footprints" of damage. T2-hyperintense lesions in patients with MS are nonspecific for the underlying pathology, which may include varying degrees of inflammation, demyelination, gliosis, edema, Wallerian degeneration, and axonal loss.
During the past few years, advanced techniques have been developed to increase the sensitivity in detecting MS-related demyelinating foci. These include fast or turbo spin-echo, 8 fluid-attenuated inversion recovery (FLAIR) (FIGS. 1 and 2), 9 and double inversion recovery (DIR). 10 There are relative advantages and disadvantages to each. For example, conventional and fast spinecho T2-weighted images are relatively less sensitive than newer techniques in detecting periventricular and cortical-juxtacortical lesions. A full review of MRI detection of GM involvement has been recently published. 11 Because FLAIR and DIR sequences suppress CSF bright signal, they detect GM lesions with greater sensitivity (FIG. 2) . 9 -13 On the other hand, FLAIR is relatively insensitive for identifying lesions in the posterior fossa and spinal cord due to flow-related artifacts. The advent of ultrahigh-field MRI (i.e., 3 Tesla [T] and higher) brings the promise of increased sensitivity for detecting MS lesions (e.g., see section on "Ultrahighfield strength MRI" as follows).
Brain T2 lesions in both cross-sectional and short-term longitudinal studies show generally weak correlations with clinical disability, as measured using the Expanded   FIG. 1 . Fluid-attenuated inversion-recovery images of a 43-year-old woman with relapsing-remitting multiple sclerosis (MS) (A-C). Note the typical hyperintense lesions, oval/ovoid in shape and seen in the periventricular white matter and juxtacortical gray-white junction. Several of the periventricular lesions directly contact the ventricular ependyma. In addition, most of the lesions are 5 mm or greater in diameter. The sagittal image (C) reveals "Dawson's fingers," characteristic of MS, believed to occur because of perivenular inflammation; the arrow indicates one of several "Dawson's fingers" seen on the sagittal image.
FIG. 2.
Fluid-attenuated inversion-recovery images (A, B) and spin-echo T2-weighted images (C, D) of a 34-year-old woman with relapsing-remitting multiple sclerosis. Note the improved conspicuousness of periventricular and cortical/juxtacortical lesions on the fluid-attenuated inversion recovery images compared to T2 images. Disability Status Scale. 3 This dissociation has been attributed to many factors, including the compensatory abilities of brain tissue, the limitations of the clinical rating scale, the failure of T2-weighted images to characterize diffuse disease, and the presence of spinal cord disease. However, the degree of T2-hyperintense lesions assumes clinical significance early in the disease course of MS and has a prognostic value in predicting conversion from a clinically isolated syndrome (CIS) to relapsing-remitting MS. 14 -17 Baseline cerebral T2-lesion volume (T2LV) combined with whole brain atrophy is a relatively strong predictor of short-term disability in patients with CIS and relapsing-remitting MS (RRMS). 18 In a 13-year longitudinal study, baseline T2LV predicted the development of brain atrophy; moreover, the change in T2LV in the first two years predicted the long-term neurological and cognitive status. T2-based qualitative and quantitative measures have been used to monitor the therapeutic value of various drugs, as we have recently reviewed. 1 All of the diseasemodifying agents approved by the Food and Drug Administration (FDA) have shown a significant benefit in limiting the progression of T2LV. However, one of the major limitations in using T2LV as a longitudinal surrogate measure is the plateauing relationship between T2LV and disability, 20 which reflects in part the engulfing of T2 lesions by the expanding CSF spaces in the midst of progressive brain atrophy and disease progression; this plateauing also probably reflects the role of diffuse occult disease in WM and GM that escapes detection with conventional MRI.
T1 hypointense lesions
A subset of T2 hyperintense MS lesions may appear hypointense on corresponding T1-weighted images (FIG.  3) . These hypointensities (also called "black holes") are commonly seen in the supratentorial brain regions and rarely seen in the posterior fossa and spinal cord. A T1-hypointense lesion most commonly develops initially as a Gd-enhancing lesion and has about a 50-50 chance of being either transient (i.e., lasting 6-12 months) or being permanent (FIG. 3) . The age and degree of T1 hypointensity reflects the underlying pathology in T1-hypointense lesions. Those that show profound hypointensity and permanence primarily reflect irreversible tissue destruction (i.e., irreversible demyelination and axonal loss) whereas those that are transient reflect edema and demyelination with subsequent remyelination. 21, 22 Not surprisingly, chronic persistent T1-hypointense lesions are associated to a moderate degree with global brain atrophy. 23, 24 However, there are technical considerations to be kept in mind with regard to T1-hypointense lesions. The degree of T1 hypointensity in lesions depends on the MRI pulse sequence, which may explain the discrepancies in the results reported among investigators. Furthermore, most previous studies of T1-hypointense lesion volume have been based on manual or semiautomated identification of lesions. 25, 26 These methods have limited efficiency and reproducibility, particularly with regard to assessing large data sets in multicenter clinical trial settings or comparing data across analysis centers. Recently, Datta et al. 27 developed an automated method based on fuzzy connectedness principles for identification and quantification of T1-hypointense lesions. This method holds promise as it involves minimal operator interaction.
Both cross-sectional and longitudinal studies indicate a moderate to strong correlation between whole brain T1-hypointense lesion load and neurological impairment. 3, 23, 28 Patients with secondary progressive (SP) MS and primary progressive (PP) MS typically show more T1-hypointense lesions as a proportion of T2-hyperintense lesions than patients with RRMS. 29 Analyses that incorporate T1-hypointense lesion volume with conventional T2 measures correlate better with neurologic impairment than T2 measures alone. 3 In addition, patients with SPMS tend to show stronger T1-hypointense lesionclinical correlation than patients with RRMS. 21, 28 The amount and duration of Gd enhancement at baseline may determine the final course of T1-hypointense lesion development. 30 However, due to the irregular nature of T1-hypointense lesion evolution, this predictive power is limited. Advanced MRI techniques, such as magnetization transfer (MT) imaging, better predict the conversion from acute to chronic T1-hypointense lesions. 31 Analyses of global T1-hypointense lesion volume change, or the effect on the evolution of newly formed individual T1-hypointense lesions, have emerged as supportive outcome measures in MS related neurotherapeutic trials, as recently reviewed. 
Blood-brain barrier compromise
The development and evolution of an MS lesion is characterized by disruption of the blood-brain barrier and migration of leukocytes into the brain parenchyma. With MRI, this process can be captured in the form of leakage of intravenously administered Gd contrast. 32 Gd enhancement is best observed with spin-echo T1-weighted images. The sensitivity in detecting such lesions can be enhanced with technical improvements, such as delivering an off-resonance MT pulse, 33 delaying the scanning by 5 minutes or more after Gd injection, 33, 34 or increasing the Gd dose 35 with ultrahigh field MRI (e.g., see section on "Ultrahigh-field strength MRI" as follows) 35 or with improved post-processing methods. 36 Gd enhancement usually precedes or accompanies new T2-hyperintense lesion formation, but disappears after an average of three to six weeks. 37 Therefore, such enhancement is not seen with the appearance of new T2 lesions unless frequent imaging is performed. Gd-enhancing lesions can be categorized into multiple morphologic types, such as concentric ring, open ring, heterogeneous, and homogeneous enhancement (FIG. 4) . Homogeneousenhancing lesions are the most commonly seen form in patients with MS. Open ring enhancement is fairly specific for MS. 38 Ring-enhancing lesions show higher levels of tissue destruction 39, 40 than homogeneously-enhancing lesions and thus tend to resolve more slowly. Moreover, ring-enhancing lesions are at high risk for conversion to chronic T1-hypointense lesions 41 and predict global brain parenchymal loss. 42 Whereas prior Gd-enhanced MRI studies focused mostly on analyzing visible enhancing lesions, emerging studies have also begun to analyze subtle blood-brain barrier disruptions that are usually missed on visual inspection. 43, 44 Using quantitative T1-relaxometry analysis, Soon et al. 44 recently demonstrated that subtle bloodbrain barrier disruption can occur in nonenhancing lesions and is seen in all clinical phenotypes and across various lesion morphologies.
The clinical MRI paradox with regard to conventional imaging manifests with Gd-enhancing lesions in several ways. Enhancing lesions often are clinically silent and therefore show a poor correlation with current clinical status. 45, 46 Such lesions are unreliable predictors of progressive disability. 47 In addition, patients with RRMS frequently show a higher frequency of enhancement than patients with progressive forms of MS. Nevertheless, their presence increases the risk of continuous disease activity 48 and the short-term appearance of clinical relapses. 46, 48, 49 All of the disease-modifying agents that are approved by the FDA for the treatment of MS show a significant effect on limiting Gd enhancement as recently reviewed. 1 Furthermore, a drug that exacerbates MS may be detected early by observing worsening Gd enhancement.
Studies from the experimental autoimmune encephalomyelitis model, an animal model of MS, indicate that macrophage infiltration into the brain parenchyma can be tracked using novel contrast agents, relying on the MRI detection of ultra small-particle iron oxides (USPIOs). USPIOs accumulate in phagocytic macrophages and thus may provide more precise information about the pathophysiologic cascade of the inflammatory events in vivo. 50, 51 In a study involving 10 patients with MS in acute relapses, Dousset et al. 52 found 33 USPIO-enhanced lesions in 9 of the 10 patients compared to 55 Gd-enhancing lesions detected in 7 of the 10 patients. Importantly, 2 USPIO-enhanced MS lesions showed no Gd enhancement; 24 lesions showed only Gd enhancement, and 31 lesions showed enhancement with both contrast agents. The investigators suggested that macrophage infiltration is mainly associated with blood-brain barrier disruption; however, it can be spatially independent, contributing to the discrepancy observed in the uptake of both contrast agents. Further studies on the significance of cell-specific agents such as USPIO will be potentially important for understanding the evolution of MS lesions and the role of macrophages/microglia.
Diagnostic criteria
Both T2-hyperintense and Gd-enhancing lesions are used in the formal diagnosis of MS. The International Panel criteria were revolutionary in allowing a characteristic change (for the first time) in MRI findings to demonstrate dissemination in time that could substitute for a second clinical attack. 53 A panel convened to update the criteria expanded it for dissemination in time. 54 Specifically, a new T2 lesion demonstrated at least one month (rather than three months) after the initial attack can be used to establish dissemination in time. They also expanded the use of spinal cord lesions in the MRI criteria for dissemination in space. With the revised criteria, a T2-hyperintense spinal cord lesion can be used as a substitute for an infratentorial brain lesion, whereas a Gd-enhancing spinal cord lesion can substitute for a Gdenhancing brain lesion. It is likely that future improvements in MRI diagnostic criteria will include a consideration of ultrahigh-field imaging, diffuse occult disease, and GM involvement once the technologies for these assessments reach maturity.
MRS
MRS is a technique that derives an MRI signal from various metabolites. The reader is referred to two recent reviews in this journal that include a discussion of the technical aspects of MRS. 55, 56 Proton MRS studies have revealed that myriad brain metabolite concentrations including N-acetylaspartate (NAA), choline (Cho), lactate (Lac), lipids, myoinositol (mI), and glutamate/glutamine are altered in patients with MS and undergo longitudinal change. 55, 57, 58 Individual metabolites are believed to reflect specific underlying pathologies. For example, in patients with MS, decreased NAA is proposed as a marker for the loss of axonal/neuronal integrity, increased Cho indicates membrane turnover such as that seen with demyelination/remyelination, increased Lac indicates energy failure, increased lipid represents myelin breakdown or necrosis, and increased mI reflects gliosis.
MRS provides insight into the sequence of events that occur during the development of MS lesions. Overt, newly formed Gd-enhancing lesions often show elevated Cho, Lac, creatinine (Cr), mI, and lipids and reduced NAA. 59, 60 In addition, glutamate levels, which can be resolved from the glutamine peak with 3 T MRI, have also been proposed to significantly rise in lesions, suggesting a link between excitatory amino acids and axonal damage perhaps due to excitotoxicity. 61 With lesion evolution, the extent of recovery of these metabolites is highly variable. In most lesions, Lac, Cho, Cr, and lipids return to normal after an initial surge suggesting resolution of edema and remyelination, with reversible metabolic changes. 58, 62, 63 However, NAA tends to remain persistently low or shows only partial recovery indicating irreversible axonal injury/loss. 62 One of the major uses of MRS is the ability to detect microscopic damage in WM and GM areas that are free of overt lesions on conventional MRI scans, such as the so-called "normal appearing white matter" (NAWM). 60, 63, 64 In NAWM, MRS shows decreased NAA, which likely reflects a loss of axonal integrity (either axonal injury, axonal loss, or both). 59, 60, 65 In addition, MRS may detect elevated Cho, mI, and lipids in NAWM. Such "pre-lesional" changes may appear months before the development of T2-hyperintense lesions, 62 indicating that intrinsic brain parenchymal changes may precede the development of overt Gdenhancement. At the earliest clinical stage of MS (in patients with CIS), mI is elevated in NAWM, whereas NAA, Cho, and lipid/Lac remain normal. 66 There is growing interest in GM involvement in MS, which includes both demyelinating lesions and neuronal loss.
11 GM changes can be detected by MRS, such as decreased NAA and lipid/Lac peaks. [67] [68] [69] [70] Various studies have looked at the clinical relevance of MRS measures in patients with MS. Such measures show relatively stronger correlations with clinical measures of disability (i.e., cognitive dysfunction and physical disability) than do conventional MRI measures. [71] [72] [73] [74] [75] [76] [77] [78] Longitudinal studies suggest that MRS measures hold promise in predicting the development of disability. [71] [72] MRS is just beginning to be applied to the study of the spinal cord in patients with MS (e.g., see section on "Spinal cord imaging" as follows for details).
Several of the disease-modifying therapies approved by the FDA have shown a significant effect on limiting the progression of MRS derived metrics, such as NAA, including the interferons and glatiramer acetate, as recently reviewed.
1,57 However, results have been variable and confined to nonrandomized small studies. In addition, the reproducibility and inter-institutional standardization of MRS data present technical challenges that are currently under investigation. 65 It remains unknown if MRS will provide a reliable and sensitive tool to monitor therapeutic effects in large multi-center phase II/III trials.
Magnetization transfer imaging
Magnetization transfer imaging (MTI) is emerging as a sensitive MRI method to detect disease activity and monitor disease progression in MS. The reader is referred to recent reviews, including one from this journal, which include a discussion of the technical aspects of MTI. 79, 80 Injury to CNS structures can cause a decrease in exchange of tissue mobile protons. This abnormality can be captured on MTI as a decreased magnetization transfer ratio (MTR) (FIG. 5) . Decreased MTR is believed to primarily reflect demyelination and axonal loss, but it is also probably affected to some extent by inflammation, gliosis, and edema.
Overt MS lesions seen on conventional MRI scans are characterized by decreased MTR compared to normal WM areas. T2-hyperintense lesions that show hypointensity on corresponding T1-weighted images usually have more profound reduction in MTR than lesions with T1 isointensity. 81, 82 The profound and persistent loss of MTR in lesions is more closely linked to physical disability than lesions with relative preservation of MTR. 80 For example, studies have found lower lesion MTR in progressive patients than in patients with early disease. 83 Similarly, patients with RRMS show lower MTR in established lesions than patients with benign MS and CIS. 84, 85 Newly appearing Gd-enhancing lesions tend to have initially low MTR, which in time can either return to normal or remain low after the enhancement has resolved. 86 -88 The degree of MTR loss in Gd-enhancing lesions at
FIG. 5. Axial magnetization transfer (MT) images and maps of a healthy control in the fourth decade (A-C) and an age-matched patient with relapsing-remitting multiple sclerosis (MS) (D-F).
The spin-echo proton density-weighted MT source images are shown with (B, E) and without (A, D) the on-resonance MT saturation radio frequency pulse. The intra-subject source images are co-registered and MT ratio (MTR) maps are generated (C, F) per our previously described method. 100 Whole-brain MTR histograms (G) are then derived from all nonbackground pixels in the MTR images (C, F). Note the patient with MS (G, red line) has a lower histogram peak height than the normal control (G, black line), despite the fact that the patient with MS is early in the course of the disease, with only mild physical disability (Expanded Disability Status Scale score of 1.5) with a disease duration of only two years. (NC ϭ normal controls.) baseline predicts the risk of conversion to chronic T1-hypointense lesions; lesions with only mild or moderate compromise in MTR at the time of enhancement are most likely to revert to T1 isointensity. 31 Profoundly reduced MTR indicates a chronic inactive lesion with axonal swelling, axonal loss, and severe demyelination. 22, 89, 90 MTI is also capable of revealing microscopic damage in normal appearing brain tissue that is free from any visible lesions on conventional MRI scans. 86, 91, 92 Many studies have demonstrated MTR changes in NAWM in all the MS phenotypic subtypes, [91] [92] [93] including patients very early in the course of the disease (FIG. 5) . A recent study found that the NAWM adjacent to T2 lesions has significantly lower MTR than regions distant to lesions, suggesting that the extent of demyelination in MS lesions is greater than that shown by conventional MRI. 94 MTI can also detect pre-lesional pathology that precedes the appearance of overt Gd-enhancing lesions by several months. 88, 95 Furthermore, MTI has been helpful in improving the ability to detect damage in GM, including the cerebral cortex and subcortical nuclei. 93, 96, 97 These changes may appear very early in the course of the disease, 93,96 -99 and they are more severe in progressive patients. 100 Conversely, the distribution of GM MTR changes reported across various studies is not consistent. One study found that even though MTR could detect damage in NAWM, it could not detect GM changes in a cohort of patients with MS as compared to normal controls. 100 MTR changes in NAWM and GM in patients with MS show moderate to strong correlations with physical disability 99,101-104 and cognitive dysfunction. [105] [106] [107] [108] Data from various longitudinal studies suggest that MTR may be a sensitive marker for predicting subsequent disability and disease progression. 103, 104, 109 MTI is beginning to be applied to the study of the spinal cord in patients with MS (e.g., see section on "Spinal cord imaging" as follows).
Several of the disease modifying therapies approved by the FDA have shown an effect on limiting the progression of MTR-derived metrics or on promoting their recovery after initial decreases, including the interferons and glatiramer acetate, as recently reviewed. 1, 79 However, results have been variable and have been mostly confined to nonrandomized small studies. The technical challenges posed by MTI include inter-institutional standardization of protocols and data obtained. Thus, it remains to be determined if MTI will provide a reliable and sensitive tool to monitor therapeutic effects in large multi-center phase II/III trials.
Diffusion imaging
Because axons are the major component of the pathophysiology of MS, any technique that sensitively captures fiber architecture should prove useful in understanding the disease. As a result, MRI diffusion imaging, including diffusion-weighted imaging or the more sophisticated diffusion tensor imaging (DTI) are of growing interest as tools to better define MS-related tissue damage and understand disease pathophysiology. The reader is referred to recent reviews, including one from this journal that includes a discussion of the technical aspects of diffusion imaging. 110, 111 Diffusion imaging is based on the detection of alterations in the direction, randomness, and velocity of water movement in tissue. DTI may be used to map the three-dimensional diffusion of water and describe the magnitude, degree, and orientation of diffusion anisotropy. In patients with MS, both demyelination and loss of axonal integrity in WM cause increased water diffusion, which can be measured by increased mean diffusivity (also known as apparent diffusion coefficient [ADC]) or decreased fractional anisotropy (FA). However, it should be kept in mind that diffusion imaging metrics are nonspecific and may also reflect gliosis, edema, and inflammation. 40, [112] [113] [114] Recent technological advances in diffusion imaging allow the derivation of radial versus axial diffusivity measures, which are proposed to provide additional specificity for myelin versus axonal integrity, respectively. 110 WM lesions in patients with MS are generally characterized by increased ADC and decreased FA. 40, 114, 115 In a small subset of lesions, particularly those with ring-like Gd enhancement, ADC may be decreased in the acute phase.
40
T2-hyperintense lesions that appear as hypointense lesions on corresponding T1-weighted images show higher ADC than those that are T1 isointense; the profound increase in ADC of T1-hypointense lesions most likely reflects severe axonal damage and myelin loss. 40, 113, 114 Schmierer et al. 116 in a postmortem study of progressive MS subjects with chronic WM lesions reported that mean diffusivity and fractional anisotropy correlated strongly with the myelin content and less strongly with axonal count. Lesion changes seen with diffusion imaging in patients with MS probably also reflect inflammation, edema, and, to a lesser extent, gliosis. Diffusion imaging can also detect tissue damage in areas free of overt lesions on conventional MRI scans in patients with MS including the NAWM. [112] [113] [114] [115] [117] [118] [119] Such involvement can be exquisitely detected with DTI, including tract-specific alterations. 117,120 -124 Combining MRI-based perfusion and diffusion imaging, one recent study found that hypoperfusion in the callosal NAWM was correlated with decreasing MD, prompting the authors to hypothesize that ischemic damage may play a role in Wallerian degeneration. 123 In patients with MS, diffusion imaging has uncovered significant GM changes, 118, 119, 125, 126 which are more readily detected than diffusion-related WM abnormalities. 126 The advances in diffusion imaging techniques have led to a growing interest in how these metrics correlate with clinical measures of MS, including physical disability, disease progression, and cognitive function. Although some past studies have shown poor correlations between diffusion measures and clinical disability, 127, 128 with advanced diffusion imaging techniques like DTI, significant correlations have been found in both cross-sectional and longitudinal studies. 115, 118, 122, 124, 129, 130 Both GM and WM diffusion changes are related to clinical progression. 126 Due to its ability to demonstrate longitudinal changes, diffusion imaging could become an outcome measure in drug trials, although this possibility remains unexplored in the published literature. Diffusion imaging is beginning to be applied to the study of the spinal cord in patients with MS (see section "Spinal cord imaging" as follows).
Brain atrophy
Progressive brain atrophy is being increasingly recognized as a manifestation of the MS disease process (FIGS. 6 and 7). Both qualitative and quantitative (twodimensional and three-dimensional) methods exist for the measurement of brain atrophy. The reader is referred to recent reviews on atrophy in MS that include a discussion of the technical aspects of MRI measurement. [131] [132] [133] The histological basis of CNS atrophy in patients with MS is not well understood. Although primarily reflecting demyelination, axonal loss and neuronal loss, other factors may also affect CNS volume, such as medication effects, fluid status, and inflammation.
Atrophy in patients with MS appears to result in part from previous inflammatory demyelination-related damage in overt lesions. For example, Jasperse et al. 134 compared conventional MRI measures including T2-lesion volume, T1-hypointense lesion volume, and Gd-enhancing lesions in predictive models of brain atrophy and concluded that T2LV was the best predictor of atrophy. In a longitudinal 14-year analysis, 135 T2-lesion accumulation in the first five years predicted subsequent brain atrophy; however, this accumulation did not account solely for the atrophy seen at 14 years. Another factor potentially contributing to atrophy is brain iron deposition that may cause secondary damage, particularly in GM. 136 Brain atrophy is typically widespread in patients with MS, including both GM and WM, and both infratentorial and supratentorial areas (FIG 6) . With various emerging techniques allowing assessment of regional brain atrophy and segmentation of GM versus WM atrophy, it has become apparent that GM is disproportionately affected compared to WM. 137 The deep gray nuclei are particularly affected by atrophy, 67,138 -140 and the rate of atrophy in the GM is higher than in the WM in the early stages of MS. 141, 142 Progressive brain atrophy (FIG. 7) has been estimated to occur at a rate of 0.6 to 1.35% per year, with the highest rate occurring in patients with active RRMS. 132 However, progressive brain atrophy occurs in all forms of MS, and can be seen early in the course of the disease (in patients with CIS or the initial stages of RRMS). [141] [142] [143] Brain atrophy has been shown to better correlate with clinical status (including both physical disability and cognitive impairment) than with conventional MRI lesion measures. 132 Several of the disease modifying therapies approved by the FDA (including the interferons, glatiramer acetate, and natalizumab) have shown a benefit on limiting progressive brain atrophy in patients with MS, although results have been somewhat variable and difficult to interpret. 132, 144 Future studies will undoubtedly explore the regional topography of such treatment effects as the relative effect on GM versus WM. 145 Atrophy measures are being incorporated into studies that explore the efficacy and safety of novel MS therapies. New data have emerged from natalizumab, 146 autologous hematopoietic stem cell transplantation, 147, 148 and testosterone. 149 In the phase III placebo-controlled natalizumab trial in patients with RRMS, the patients receiving active therapy had a higher rate of brain volume loss in the first year than patients receiving a placebo, whereas the opposite was seen in the second year. 146 Similarly, in patients receiving autologous hematopoietic stem cell transplantation, a faster rate of brain volume loss was observed in the first few months than in the pre-treatment period. 147 However, subsequently, the treatment appears to slow the rate of atrophy. 148 These results combined with data from previous studies with interferon agents indicate that immunomodulatory agents may reduce brain volume in the first few months by their direct effect on reducing inflammation rather than by accelerating demyelination and axonal loss. One of the clear limitations in using brain atrophy as a longitudinal marker of drug efficacy are the acute effects of medications on brain volume that confound the measurement of true atrophy.
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T1-and T2-based measures of diffuse brain injury T1 Imaging. T1-relaxation times obtained by T1-mapping approaches have been shown to be sensitive, but not specific for underlying pathology in the brain and spinal cord of patients with MS, as recently reviewed. 151 Such measures can detect diffuse damage in areas of the CNS that are free of overt lesions on conventional MRI scans. 94, [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] Furthermore, T1 mapping may be more sensitive than MTR in detecting tissue damage in NAWM. 94 The most common effect of MS on T1 relaxation is prolongation, which is believed to result from a variety of processes such as edema, demyelination, gliosis, and axonal loss in NAWM profound prolongation of T1 is seen when comparing patients with SPMS to patients with RRMS 160 and in patients with early RRMS versus normal controls.
161
T1-mapping data have shown weak to moderate correlations with physical disability. 151, 154, 156 Increases in WM relaxation times have been shown to correlate with brain atrophy. 152, 154 Increases in deep GM T1-relaxation times correlate significantly with MS fatigue. 158 However, one should bear in mind that the disease process may cause T1 shortening (perhaps related to macrophage activity or metal deposition) 157, 162 as opposed to T1 prolongation. This offsetting factor might limit the longitudinal sensitivity of T1 mapping measures.
T2 Imaging.
As recently reviewed in this journal, 163 many GM areas (including the thalamus, dentate nucleus, basal ganglia, and rolandic cortex) commonly show hypointensity on T2-weighted images in patients with MS. Iron deposition has been postulated to be a cause of this hypointensity, as it reduces T2-relaxation times and is found pathologically to be in excess in the MS brain. 164 Furthermore, biochemical abnormalities related to iron are seen in patients with MS. 163 It remains unclear whether iron deposition contributes to secondary damage or is purely an epiphenomenon. T2 hypointensity in GM has been related to brain atrophy, physical disability, and cognitive impairment in patients with MS. 136, [165] [166] [167] [168] Prior studies determining T2 hypointensity have relied on normalized intensity measurements rather than relaxometric studies. Advanced methods such as T2 relaxometry and gradient-echo imaging with ultrahigh-field MRI should increase our understanding of the role iron plays in the pathophysiology of MS in the future. 151 As reviewed recently in this journal, 169 T2-relaxometry techniques have also been useful in evaluating the short component of the T2-relaxation curve in NAWM and overt lesions in patients with MS. The short T2 component is believed to reflect the myelin content. Reduced myelin detected by this technique has been reported in both lesions 170 -173 and NAWM. 170 An exciting advance in this area was recently reported by Oh et al., 174 demonstrating the role of 3 T MRI in detecting decreased myelin content in NAWM in patients with MS.
Spinal cord imaging
Neuropathologic studies have demonstrated both demyelinating plaques and atrophy of the spinal cord of MS patients. A pathologic study estimated that up to 90% of MS patients have lesions in their cervical spinal cord. 175 Approximately 30% of patients presenting with clinically isolated optic neuritis show evidence of spinal cord disease at the time of presentation. 176 Demyelination in the cord affects both GM and WM. 177 Conventional MRI has revealed that patients with RRMS tend to have focal T2 hyperintensity while patients with PPMS and SPMS additionally are likely to have confluent lesions. Gd enhancement is seen less frequently in the spinal cord than in the brain, and T1 hypointensity in the spinal cord is rare. Lesions in the spinal cord are often associated with clinical symptoms.
Conventional MRI of the spinal cord in MS has lagged behind that of brain MRI due to technical limitations of spinal cord imaging. 178 The correlations in cross-sectional and longitudinal studies of spinal cord lesions with clinical involvement have been moderate at best. 179 Cord atrophy, on the other hand, has shown better correlation with disability. 180 Recently, Carbonell-Caballero et al. 181 showed that an automated method of calculating cervical cord volume was highly accurate and sensitive to spinal cord atrophy in patients with MS. Automation has the benefits of improving reliability and significantly reducing processing time, and should generate additional interest in the near future. Advanced MRI techniques are of growing interest to add more specificity and sensitivity to the non-invasive evaluation of spinal cord disease in patients with MS. These include MTI, diffusion imaging, and MRS. DTI of the spinal cord has been recently reviewed both from a clinical and technical standpoint in this journal. 182 DTI performed in the cervical cord of patients with MS typically shows decreased FA and increased mean diffusivity compared to controls and correlates significantly with disability. [183] [184] [185] MRS is just beginning to be applied to the study of the spinal cord in MS. When compared to healthy controls, reduced NAA was seen in the NAWM of the cervical cord of MS patients. 186 Recently, a protocol enabling MRS for use in spinal imaging has been developed on a 3 T platform. 187 Average MTR in the spinal cord of patients with RRMS or CIS does not differ significantly from normal controls. 188 MTR also did not differ between patients with PPMS versus SPMS, 189 although patients with PPMS showed lower MTR than patients with RRMS. 
Ultrahigh-field strength MRI
The availability of ultrahigh-field strength scanners (i.e., 3 T and higher) has the potential to revolutionize research and clinical care in MS. Such scanners reveal MS lesions in the brain with more sensitivity than 1.5 T scanners (FIG. 8) . 190 -195 Keiper et al. 190 found that observers were able to consensually detect more lesions at 4 T than 1.5 T, including the ability to distinguish perivascular lesions from normal perivascular spaces. Furthermore, cerebral lesion volume tends to increase as magnet strength increases. 190 In a study involving 25 patients with MS, Sicotte et al. 192 showed an increased number and volume of Gd-enhancing lesions and increased volume of T-2 hyperintense lesions at 3 T versus 1.5 T. Wattjes et al. 193 scanned 40 patients with CIS at 1.5 T and 3 T and determined that 11 additional patients fulfilled MS diagnostic criteria at the higher, rather than lower, field strength.
Ultrahigh-field imaging has particular relevance in the detection of cortical lesions in patients with MS. Wattjes et al. 13 studied nine patients with MS using DIR, FLAIR, and T2-weighted sequences at 3 T and found that DIR was more sensitive in detecting lesions than FLAIR or T2 especially in the infratentorial region. Both DIR and FLAIR showed higher lesion counts in detecting juxtacortical, mixed WM and GM, and periventricular lesions when compared to conventional T2 sequences. In an MRI histologic correlation study, Kangarlu et al. 191 recently found that 8 T revealed many plaques that were undetected at 1.5 T, particularly those in the cerebral cortex.
Ultrahigh-field MRI also has applications to improving MRS, 61 MTI, 196 DTI, 111 and relaxometry studies 151, 174 in MS. However, several challenges remain in using ultrahigh-field MRI. Acquisition protocols are still being developed and optimized. Patient safety issues and artifacts are being understood and addressed. 195, 197 
CONCLUSIONS
We have reviewed the current understanding of conventional and advanced MRI techniques used in the study of patients with MS. We have seen that the role of conventional MRI measures has far exceeded its primary objective of diagnosis and management of MS. However, these conventional measures show only moderate correlations with neurological impairment and disease progression, and remain generally nonspecific for the underlying pathology. Advanced MRI techniques hold promise in uncoupling the MRI clinical paradox and may contribute to a more sensitive and specific depiction of clinically relevant underlying pathology. These advanced techniques continue to define the future of MS research using MRI. We conclude that MRI has witnessed unprecedented growth and development during the past several years and continues to provide an expanding toolbox to uncover the complexities of this intriguing disease. 
